EL7.AI
StocksMedium•31 March 2026•
1 min read

Agios Pharmaceuticals to Seek Accelerated FDA Approval for Mitapivat in Sickle Cell Disease

Key Facts

1Agios Pharmaceuticals announced it will pursue U.S. accelerated approval for mitapivat in sickle cell disease.
2The decision follows a successful pre-sNDA meeting with the U.S. Food and Drug Administration (FDA).
3The company plans to submit the sNDA in the coming months and is aligning with the FDA on the required confirmatory trial.

Agios Pharmaceuticals (Nasdaq: AGIO) announced its intention to pursue accelerated approval from the U.S. Food and Drug Administration (FDA) for its drug mitapivat. The treatment is designed for patients suffering from sickle cell disease, a chronic and debilitating blood disorder. This strategic decision follows a successful pre-sNDA meeting with the regulator, which confirmed the viability of the accelerated approval pathway. The company is currently working with the FDA to align on the design of a required confirmatory trial to support the submission. Agios plans to formally submit the supplemental New Drug Application (sNDA) in the coming months. Investors view this development as a significant step toward shortening the timeline for commercializing a key pipeline asset.